KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Long-Term Deferred Tax (2018 - 2020)

Ionis Pharmaceuticals (IONS) has 5 years of Long-Term Deferred Tax data on record, last reported at $307.7 million in Q3 2020.

  • For Q3 2020, Long-Term Deferred Tax rose 7.98% year-over-year to $307.7 million; the TTM value through Sep 2020 reached $307.7 million, up 7.98%, while the annual FY2019 figure was $305.6 million, 5.08% up from the prior year.
  • Long-Term Deferred Tax reached $307.7 million in Q3 2020 per IONS's latest filing, up from $306.0 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $309.6 million in Q1 2020 and bottomed at $276.4 million in Q2 2019.
  • Average Long-Term Deferred Tax over 3 years is $294.8 million, with a median of $298.2 million recorded in 2018.
  • Peak YoY movement for Long-Term Deferred Tax: grew 5.08% in 2019, then rose 11.67% in 2020.
  • A 3-year view of Long-Term Deferred Tax shows it stood at $290.8 million in 2018, then grew by 5.08% to $305.6 million in 2019, then rose by 0.71% to $307.7 million in 2020.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $307.7 million in Q3 2020, $306.0 million in Q2 2020, and $309.6 million in Q1 2020.